primary membranous nephropathy
Conditions
Interventions
HCQ group :hydroxychloroquine
Sponsors
Renal Division, Peking University First Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with biopsy-proven primary MN; 2. Aged 18-70 years old; 3. Persistent proteinuria 2-6g/d with supportive therapy including angiotensin-converting enzyme inhibitors (ACEis) and/or angiotensin-receptor blockers (ARBs) for >= 3 months; 4. Blood pressure =60ml/min/1.73m; 6. Maintain a stable diet and sodium intake during the study; 7. Sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients who were treated with steroids or immunosuppressive therapy within the previous 3 months; 2. Urinary protein fluctuated > 2g/d; 3. Patients who were not suitable for HCQ treatment because of allergy or macular degeneration; 4. the presence of uncontrolled hypertension, malignance, liver dysfunction, pregnancy or lactation; 5. using tamoxifen; 6. life expectancy less than 6 months; 7. participating in other clinical studies; 8. other circumstances considered unsuitable for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| proteinuria; | — |
Secondary
| Measure | Time frame |
|---|---|
| eGFR;anti-PLA2R antibody; | — |
Countries
China
Contacts
Public ContactZhao Minghui
Renal Division, Peking University First Hospital
Outcome results
None listed